Amylin seems to be easier on the gut than GLP-1s like Ozempic, though it may produce less weight loss. advertisement. Barron's. ... kidneys and perhaps even the brain.

Summary. AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk.

Amylin, a satiety hormone, has been identified as a potential therapeutic target for the treatment of obesity given its role in activating signals to the brain that result in appetite suppression ...